- Home
- SRBK vs MAIA Comparison
SRBK vs MAIA Comparison
Compare SRBK & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRBK
- MAIA
- Stock Information
- Founded
- SRBK 1887
- MAIA 2018
- Country
- SRBK United States
- MAIA United States
- Employees
- SRBK N/A
- MAIA N/A
- Industry
- SRBK
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- SRBK
- MAIA Health Care
- Exchange
- SRBK Nasdaq
- MAIA Nasdaq
- Market Cap
- SRBK 96.1M
- MAIA 62.4M
- IPO Year
- SRBK N/A
- MAIA 2022
- Fundamental
- Price
- SRBK $10.67
- MAIA $2.82
- Analyst Decision
- SRBK
- MAIA
- Analyst Count
- SRBK 0
- MAIA 0
- Target Price
- SRBK N/A
- MAIA N/A
- AVG Volume (30 Days)
- SRBK 20.6K
- MAIA 60.0K
- Earning Date
- SRBK 01-01-0001
- MAIA 11-05-2024
- Dividend Yield
- SRBK N/A
- MAIA N/A
- EPS Growth
- SRBK N/A
- MAIA N/A
- EPS
- SRBK N/A
- MAIA N/A
- Revenue
- SRBK $22,814,000.00
- MAIA N/A
- Revenue This Year
- SRBK N/A
- MAIA N/A
- Revenue Next Year
- SRBK N/A
- MAIA N/A
- P/E Ratio
- SRBK N/A
- MAIA N/A
- Revenue Growth
- SRBK 52.54
- MAIA N/A
- 52 Week Low
- SRBK $8.01
- MAIA $0.82
- 52 Week High
- SRBK $11.24
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- SRBK 51.76
- MAIA 50.98
- Support Level
- SRBK $10.97
- MAIA $2.36
- Resistance Level
- SRBK $11.09
- MAIA $2.72
- Average True Range (ATR)
- SRBK 0.06
- MAIA 0.22
- MACD
- SRBK -0.05
- MAIA 0.02
- Stochastic Oscillator
- SRBK 5.50
- MAIA 72.28
About SRBK SR Bancorp Inc. Common stock
SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.